A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Summary

To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.

Timeline

Start

2016-08-26

Primary completion

2017-10-23

Completion

2017-11-27

Drugs

Indications